● neutral
Impact
PhasePhase 1
Time to marketUnknown — the drug is in early Phase 1 dose-escalation. Assuming successful development, a potential approval would be several years away (likely 2029+).
FHD-909 Updated Sep 4
What to watch
Monitor for any announced Phase 1 data readout date or interim results from the FHD-909 dose-escalation trial, which would be the next major catalyst. Also watch the December 2026 Lilly collaboration term expiration for potential restructuring or milestone news. The stock's ~144% implied upside to analyst targets reflects optimism about the platform, but early-stage clinical risk remains substantial.
Bull case
- Preclinical data at AACR 2026 showed complete and durable tumor regression with FHD-909 + anti-PD-1 combination, plus anti-tumor immune memory, a strong signal for a differentiated mechanism in SMARCA4-mutant NSCLC.
- Analyst consensus is Strong Buy (15 Buy/Strong Buy vs 1 Hold) with a mean price target of $11.44, implying ~144% upside from the current ~$4.92 price.
- FHD-909 is partnered with Eli Lilly (code LY4050784), providing validation and potential milestone/revenue support; Foghorn had $167.6M cash as of Q2 2026 with runway into H1 2028.
Bear case
- FHD-909 is in early Phase 1 dose-escalation, no human efficacy data yet; preclinical results often fail to translate to patients.
- The Lilly collaboration research term expires in December 2026, creating a potential revenue cliff and uncertainty about future partnership terms.
- Foghorn's CBPd-171 (FHT-171) program was delayed due to a CRO operational issue, raising concerns about broader execution risk.